BeOne Medicines Executive and Leadership Team

John Oyler, the Co-Founder, Chairman & Chief Executive Officer at BeOne Medicines, directs the overarching strategy and vision for the global biotechnology company. Oyler architects the company's approach to developing next-generation cancer treatments, ensuring alignment with the core mission of making therapies accessible worldwide. This leadership role involves guiding research and development initiatives, fostering strategic partnerships, and championing the principles of speed, equity, and affordability in patient care delivery. By maintaining a global perspective, Oyler drives the expansion of life-saving therapies, aiming to significantly improve patient outcomes across diverse markets. The Chief Executive Officer's focus remains on establishing BeOne Medicines as a leader in innovative oncology solutions, addressing unmet medical needs with urgency and precision. John Oyler's strategic direction ensures the company's operations consistently reflect its commitment to global health equity and impactful cancer treatment delivery.

Aaron Rosenberg, the Chief Financial Officer at BeOne Medicines, directs the financial strategy and fiscal management of the global biotechnology company. Rosenberg ensures the financial viability and sustainability required to support the development and worldwide distribution of innovative cancer treatments. This executive role involves overseeing all financial operations, including budgeting, forecasting, and capital allocation, with a keen focus on affordability and equity in patient care. The Chief Financial Officer's responsibilities extend to securing funding and managing investments that accelerate the company's mission to expand access to life-saving therapies. Aaron Rosenberg's financial acumen is critical in balancing the imperative for rapid treatment delivery with the commitment to making these therapies accessible to patients globally. Rosenberg's leadership ensures that financial resources are strategically deployed to maximize impact and improve patient outcomes.

Xiaobin Wu, the Co-President & Chief Operating Officer at BeOne Medicines, orchestrates the operational execution of the company's global strategy for developing and delivering next-generation cancer treatments. Wu ensures that all operational facets align with the core principles of speed, equity, and affordability, driving efficiency across research, manufacturing, and distribution. This leadership position is vital for translating scientific innovation into tangible patient benefits on a worldwide scale. The Chief Operating Officer's oversight guarantees that BeOne Medicines can effectively expand the reach of its life-saving therapies to diverse patient populations. Xiaobin Wu's operational expertise is fundamental to achieving the company's mission of improving cancer patient outcomes by making advanced treatments accessible globally. Wu's management ensures seamless integration of all operational components to maximize therapeutic impact.

Yiwei Yu, the Chief of Staff To Global President and Chief Operating Officer at BeOne Medicines, provides essential support in executing the company's global operational and strategic objectives. Yu facilitates the coordination of key initiatives, ensuring that the development and delivery of innovative cancer treatments adhere to the company's standards of speed, equity, and affordability. This role involves streamlining communication and operational workflows between the Global President and Chief Operating Officer and other executive functions. The Chief of Staff's contributions are critical in advancing BeOne Medicines' mission to expand access to life-saving therapies worldwide. Yiwei Yu's diligent support helps optimize operational efficiency, directly contributing to improved patient outcomes and the broader availability of advanced cancer care. Yu ensures that strategic operational plans are implemented effectively across all global activities.

Danielle Abatemarco, the Chief of Staff at BeOne Medicines, provides critical operational and strategic support across the executive leadership team. Abatemarco facilitates the seamless execution of company initiatives, ensuring that the development and delivery of next-generation cancer treatments align with BeOne Medicines' global mission. This role involves coordinating cross-functional efforts, managing key projects, and enhancing communication channels to support the company's commitment to speed, equity, and affordability. The Chief of Staff works closely with various departments to streamline processes and drive operational efficiency, contributing directly to the company's goal of expanding access to life-saving therapies. Danielle Abatemarco's contributions are vital in translating strategic objectives into tangible actions that improve patient outcomes worldwide. By optimizing internal operations, Abatemarco ensures the company effectively addresses the global challenge of cancer treatment accessibility.

Marcello Damiani, the Chief Technology Officer at BeOne Medicines, spearheads the technological innovation essential for developing cutting-edge cancer therapies. Damiani oversees the integration of advanced research methodologies and state-of-the-art technologies to accelerate the creation of next-generation treatments. This leadership position involves managing the company's technological infrastructure, ensuring its robustness and scalability to support global operations. The Chief Technology Officer plays a crucial role in translating scientific discoveries into viable therapeutic solutions, emphasizing the company's commitment to speed and efficacy. Marcello Damiani's expertise drives the technological advancements that underpin BeOne Medicines' mission to deliver accessible and affordable cancer care worldwide. By championing technological excellence, Damiani directly contributes to improving patient outcomes and expanding the reach of life-saving treatments across international markets.

Nancy Lam, the Vice President, Global Product & Team Leader & Solid Tumors Chief of Staff at BeOne Medicines, drives the strategic development and execution of solid tumor cancer treatments. Lam leads global product initiatives, ensuring that therapeutic advancements meet the highest standards of efficacy and patient benefit. This multifaceted role involves coordinating cross-functional teams to accelerate product development timelines and enhance market accessibility, reflecting the company's commitment to speed and equity. The Vice President's focus on solid tumors directly addresses a critical area of unmet medical need in oncology. Nancy Lam's leadership ensures that BeOne Medicines' innovative therapies are brought to patients worldwide efficiently and affordably. By bridging product strategy and operational execution, Lam significantly contributes to improving patient outcomes and expanding the reach of life-saving cancer care globally.

Wendy Shagena, the Manager, Quality Assurance & Chief Marketing Officer, Vendor Management at BeOne Medicines, ensures the integrity and compliance of the company's therapeutic products and manages critical vendor relationships. Shagena oversees quality assurance processes, guaranteeing that all cancer treatments meet rigorous safety and efficacy standards before reaching patients globally. This dual-focused role also involves strategic vendor management, optimizing partnerships to support the efficient and affordable delivery of next-generation therapies. The Chief Marketing Officer, Vendor Management aspect ensures robust supply chains and cost-effectiveness, aligning with BeOne Medicines' mission of accessibility. Wendy Shagena's dedication to quality and strategic vendor oversight is fundamental to expanding the reach of life-saving treatments and improving patient outcomes worldwide. Shagena's work upholds the company's commitment to excellence in every facet of its operations.

Kevin Zhou, the Chief Marketing Officer & Manager at BeOne Medicines, directs the strategic marketing initiatives to enhance the global reach and accessibility of innovative cancer treatments. Zhou oversees the development and implementation of comprehensive marketing strategies that communicate the value and impact of BeOne Medicines' cutting-edge therapies. This role is crucial in ensuring that patients worldwide are aware of and can access these life-saving advancements, emphasizing the company's commitment to equity and affordability. The Chief Marketing Officer's efforts focus on building brand awareness and fostering patient engagement across diverse international markets. Kevin Zhou's leadership in marketing directly supports the company's mission to improve cancer patient outcomes by facilitating broader access to novel treatments. Zhou's strategic vision drives the effective dissemination of information about BeOne Medicines' groundbreaking work.

Chun Yi, the Global Statistics & Data Science Chief of Staff at BeOne Medicines, enhances the strategic application of statistical analysis and data science in developing cutting-edge cancer treatments. Yi oversees the integration of advanced data-driven insights to accelerate research and optimize the efficacy of next-generation therapies. This role is pivotal in ensuring that BeOne Medicines leverages data science to achieve its goals of speed, equity, and affordability in patient care delivery. The Chief of Staff's focus on statistics and data science supports the company's commitment to making life-saving treatments accessible globally. Chun Yi's expertise drives innovation in therapeutic development, directly contributing to improved patient outcomes by informing precise and effective treatment strategies. Yi ensures that data science capabilities are fully aligned with the company's mission to combat cancer worldwide.